Company news

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A (SSE:688553) news

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A news releases on 6ix. Latest, Sep 23, 2026: "SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Progress…

Sichuan Huiyu Pharmaceutical Co. Ltd. Class A (SSE:688553) news

Press releases & updates

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Passive Shareholding Reduction Plan by Shareholder Holding More Than 5% of the Shares

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Provision for Asset Impairment for the First Half of 2026

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of HY07121 for Injection (Subcutaneous Injection)

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining Overseas Marketing Authorization for the Company's Products

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Controlled Subsidiary's Acceptance of Financial Assistance from Related Parties

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Proposed Selection in the National Centralized Drug Procurement

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Progress of Joint Investment with Professional Institutions to Establish a Private Equity Fund

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Progress of Signing the National General Agency Agreement and Filing a Lawsuit

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Completion of Involuntary Share Reduction Plan by Shareholder Holding More Than 5% of Shares and Results of the Share Reduction

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Receiving Government Subsidies

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Expiration of Shareholding Reduction Plan for Shareholders and Results of Shareholding Reduction

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Abnormal Fluctuations in Stock Trading

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Signing a Strategic Cooperation Agreement

"SICHUAN HUIYU PHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of HY-1016 Sustained-release Injection Obtaining Notice of Approval for Drug Clinical Trial

Announcement on Initially Granting Restricted Stocks to Incentive Objects of the 2026 Restricted Stock Incentive Plan

Announcement on Voluntary Disclosure of Obtaining Overseas Marketing Authorization for the Company's Product

Announcement on Change of Sponsor Representative

Announcement on Voluntary Disclosure of Notice of Acceptance for Drug Clinical Trial Obtained by HY07121 Injection (Subcutaneous Injection)

Announcement on Implementation of Dividend Distribution for 2025

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Announcement on Progress in Providing Guarantees for Wholly-owned Subsidiaries

Announcement on Election of Employee Representative Directors for the 3rd Board of Directors

Publicity Description and Verification Opinions of the Remuneration and Appraisal Committee of the Board of Directors on the List of Incentive Objects in the 2026 Restricted Stock Incentive Plan

Announcement on Rotary Freezing of Shares Held by Shareholder with Over 5% Shares

Announcement on Progress in Investment Cooperation Between Wholly-owned Subsidiary and Private Fund and Related Party Transactions

Announcement on the Cancellation of Some Stock Options under the 2020 Stock Option Incentive Plan

Announcement on Shareholding Reduction Plan_2026-04-23

Announcement on Voluntary Disclosure of Notice of Acceptance for Drug Clinical Trial Application Obtained by HY-1016 Sustain-released Injection

Indicative Announcement on Postponing Term Change of the Board of Directors and Term Expiration of Partial Independent Directors

Announcement on Abnormal Fluctuations in Stock Trading

Announcement on Shareholding Reduction Plan for Shareholders

Announcement on Voluntary Disclosure of Drug Registration Certificate Obtained for Carfilzomib for Injection

Announcement on Conducting Foreign Exchange Hedging Business

Correction Announcement on Preliminary Earnings Estimate for 2025

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Voluntary Disclosure of Approval of Etoposide Injection and Fluorouracil Injection by the U.S. FDA

Announcement on Voluntary Disclosure of Subsidiary Passing On-site Inspection by FDA

Announcement on Result of Passive Shareholding Reduction by Shareholder with Over 5% Shares

Announcement on Expected Loss in Performance for 2025

Announcement on Passive Shareholding Reduction Plan for Shareholders with Over 5% Shares

Announcement on Estimated Daily Related Party Transactions in 2026

Announcement on Voluntary Disclosure of Clinical Study Cooperation with AstraZeneca

Announcement on Obtaining Drug Registration Certificate for Cimetidine Injection

Announcement on Progress in Participation in Private Equity Fund Investment and Related Party Transaction

Announcement on Obtaining Drug Registration Certificate for Nicardipine Hydrochloride Injection

Announcement on Cooperation with Professional Institutions to Invest in the Establishment of a Private Equity Fund